Celcuity Inc. Projects $2 Billion Revenue for Gedatolisib as Phase 3 Trials Progress
Celcuity Inc. is poised for growth with a $2 billion peak revenue potential for its flagship drug gedatolisib, a promising development in the biotechnology industry.
2 minutes to read